Fulcrum Plummets 50% After FDA Concerns Force Scrapping of Lead Sickle-Cell Drug
FULC is trading near its 52-week low of $5.88 (45% below the low) on elevated volume (3.4× avg).
Summary
Fulcrum Therapeutics has discontinued its lead sickle-cell disease drug, pociredir, due to FDA safety concerns over malignancy risks associated with drugs targeting the PRC2 protein complex. This follows the company's positive clinical data for pociredir reported in late April and an initial announcement of the discontinuation yesterday evening. The stock plummeted 50% in premarket trading, reflecting the catastrophic loss of its primary pipeline asset. Fulcrum is now exploring strategic alternatives, including a potential sale or merger, and implementing cost cuts to preserve its $333.3 million cash balance. This event fundamentally alters the company's future and investment thesis.
At the time of this announcement, FULC was trading at $3.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $427.8M. The 52-week trading range was $5.88 to $15.74. This news item was assessed with negative market sentiment and an importance score of 10 out of 10. Source: Reuters.